Alliance Capital Management L.P. (AB) 23.44 $AB AB

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alliance Capital Management L.P. (AB) 23.44 $AB

AB Science announces the publication in the Journal of Neuroinflammation of preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis
GlobeNewswire - Mon Jul 11, 12:50AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announces the publication of preclinical study results with masitinib in amyotrophic lateral sclerosis (ALS). Entitled, 'Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis' this article and its accompanying Online Supplementary Material are freely accessible online from the peer-reviewed scientific review Journal of Neuroinflammation: DOI:10.1186/s12974-016-0620-9; https://jneuroinflammation.biomedcentral.com/articles.
AB: 23.44 (-0.09)

AB Announces Agreement In Principle To Assume Management Of Visium Global Fund
PR Newswire - Fri Jun 17, 3:56PM CDT
AllianceBernstein L.P. ("AB" , a leading global investment firm with $487 billion in assets under management, announced today that it has signed a letter of intent under which AB would assume management of Visium Asset Management's Global Fund, a multisector long/short equity hedge fund. As part of the transaction, the Visium Global Fund's investment team and certain support staff would join AB.
AB: 23.44 (-0.09)

AB Announces May 31, 2016 Assets Under Management
PR Newswire - Thu Jun 09, 3:24PM CDT
AllianceBernstein L.P. ("AB" and AllianceBernstein Holding L.P. ("AB Holding" (NYSE: AB) today announced that preliminary assets under management increased to $487 billion during May 2016 from $483 billion at the end of April. Firmwide net inflows largely drove the 0.8% increase, though market appreciation contributed as well. The Institutions channel represented the largest share of total net inflows, followed by Retail and Private Wealth Management.
AB: 23.44 (-0.09)

AB Science will hold an Investor & Analyst conference on masitinib in Amyotrophic Lateral Sclerosis (ALS) in New York, USA, on June 13, 2016
GlobeNewswire - Wed Jun 08, 10:54AM CDT
Following recommendation by the European Medicines Agency (EMA) to file masitinib for conditional marketing authorization in Amyotrophic Lateral Sclerosis (ALS), AB Science is holding an Investor & Analyst conference in New York on June 13, 2016
AB: 23.44 (-0.09)

AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization
GlobeNewswire - Mon Jun 06, 12:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announced today that Rapporteurs appointed by the European Medicines Agency (EMA) have recommended the filing of masitinib in combination with riluzole in the treatment of adult patients with amyotrophic lateral sclerosis (ALS) for conditional marketing authorization.
AB: 23.44 (-0.09)

AB Science Will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21st Congress of the European Hematology Association
GlobeNewswire - Mon May 30, 12:57AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that results from its phase 3 trial in severe systemic mastocytosis will be presented as an oral presentation at the 21 Congress of the European Hematology Association (June 9 - 12, 2016, Copenhagen, Denmark).
AB: 23.44 (-0.09)

Lazard (LAZ) Hit by Economic Headwinds: Time to Sell?
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:19AM CDT
We have issued an updated research report on Lazard Ltd. (LAZ) on May 23. Shares of this asset manager recorded a year-to-date negative return of 20.4%.
AB: 23.44 (-0.09), LAZ: 31.64 (-0.45), AMG: 142.42 (-1.32), GBL: 33.89 (+0.01)

Affiliated Managers (AMG) is a Must-Add Now: Here's Why
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:17AM CDT
From recording 6-year (2010--2015) CAGR of 13.8% in assets under management to holding an almost unbeaten track record of buying equity interests in asset management companies with strong performance-oriented products, Affiliated Managers Group Inc. (AMG), has been firing on all cylinders of late.
APAM: 27.65 (-0.75), AB: 23.44 (-0.09), AMG: 142.42 (-1.32), GBL: 33.89 (+0.01)

Eaton Vance (EV) Q2 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 23, 5:31AM CDT
Will Eaton Vance (EV) disappoint yet again? Or will it surpass earnings estimates this quarter? Let's see how things have shaped up for this announcement.
AB: 23.44 (-0.09), AMG: 142.42 (-1.32), WAL: 33.97 (-0.14), EV: 36.82 (+0.18)

AB Announces April 30, 2016 Assets Under Management
PR Newswire - Tue May 10, 3:04PM CDT
AllianceBernstein L.P. ("AB" and AllianceBernstein Holding L.P. ("AB Holding" (NYSE: AB) today announced that preliminary assets under management increased to $483 billion during April 2016 from $479 billion at the end of March. The 0.8% increase resulted from market appreciation, including the positive impact of foreign currency moves against the dollar, partially offset by firmwide net outflows. By channel, net flows were positive in Retail and negative in Institutions and Private Wealth Management.
AB: 23.44 (-0.09)

AllianceBernstein Has Returned 19.1% Since SmarTrend Recommendation (AB)
Comtex SmarTrend(R) - Wed May 04, 12:50AM CDT
SmarTrend identified an Uptrend for AllianceBernstein (NYSE:AB) on February 25th, 2016 at $19.23. In approximately 2 months, AllianceBernstein has returned 19.12% as of today's recent price of $22.90.
AB: 23.44 (-0.09)

AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis
GlobeNewswire - Mon May 02, 12:53AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the filing for registration to European Medicines Agency (EMA) for masitinib in the treatment of adult patient with severe systemic mastocytosisunresponsive to optimal symptomatic treatment, with date of review process starting on 26 April 2016. Masitinib is the first treatment to be evaluated in this indication. Top-line results from this phase 3 were previously announced on 30 November 2015.
AB: 23.44 (-0.09)

Choice Hotels International Signs Master Development Agreement To Enter Middle East
PR Newswire - Thu Apr 28, 8:26AM CDT
Choice Hotels International, Inc., one of the largest hotel companies in the world, announced today the signing of a master development agreement with Equinox Ventures Ltd, a joint venture between Equinox Group Ltd. and Al Tayyar Travel Group, to introduce and develop three of Choice's most prominent brands: Clarion, Comfort and Quality across the UAE and Saudi Arabia. This announcement, its fifth EMEA market portfolio expansion in the past six months, is part of Choice's strategy to continue to expand its brand internationally.
AB: 23.44 (-0.09), CHH: 48.20 (-0.23)

AllianceBernstein posts 1Q profit
Automated Insights - Thu Apr 28, 7:54AM CDT
NEW YORK (AP) _ AllianceBernstein Holding LP (AB) on Thursday reported first-quarter profit of $55.7 million.
AB: 23.44 (-0.09)

Uptrend Call Working As AllianceBernstein Stock Rises 27.0% (AB)
Comtex SmarTrend(R) - Tue Apr 26, 1:15PM CDT
SmarTrend identified an Uptrend for AllianceBernstein (NYSE:AB) on February 25th, 2016 at $19.23. In approximately 2 months, AllianceBernstein has returned 27.05% as of today's recent price of $24.43.
AB: 23.44 (-0.09)

AB Successfully Closes a Second Commercial Real Estate Debt Fund and Aggregate Commitments Surpass $2.3 Billion
PR Newswire - Wed Apr 20, 10:19AM CDT
AllianceBernstein L.P. ("AB" , a leading global investment management firm, today announced the closing of its second commercial real estate debt fund with total commitments of $1.55 billion, surpassing its $1 billion target. AB's second fund ("Fund II" received commitments from a diverse range of global insurers, pensions, and foundations and closed at a size double the $750 million predecessor fund, AB Commercial Real Estate Debt Series I-B ("Fund I" . In connection with Fund II's closing, investors for Fund I also extended their commitment period which increased total commitments in AB's private commercial real estate credit platform to in excess of $2.3 billion.
AB: 23.44 (-0.09)

21.9% Return Seen to Date on SmarTrend AllianceBernstein Call (AB)
Comtex SmarTrend(R) - Tue Apr 19, 1:35AM CDT
SmarTrend identified an Uptrend for AllianceBernstein (NYSE:AB) on February 25th, 2016 at $19.23. In approximately 2 months, AllianceBernstein has returned 21.87% as of today's recent price of $23.43.
AB: 23.44 (-0.09)

AB to Report First Quarter 2016 Results on Thursday, April 28, 2016
PR Newswire - Thu Apr 14, 12:23PM CDT
AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that First Quarter 2016 financial and operating results will be released on Thursday, April 28, 2016. Management will conduct a teleconference call beginning at 8:00 am (ET), following the release of its financial results. The call will be hosted by Peter S. Kraus, Chairman and Chief Executive Officer, and John C. Weisenseel, Chief Financial Officer.
AB: 23.44 (-0.09)

AllianceBernstein, Equinix, Facebook, Etsy and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 8:30AM CDT
AllianceBernstein, Equinix, Facebook, Etsy and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
VNET: 10.20 (+0.06), AB: 23.44 (-0.09), EQIX: 386.17 (-1.03), FB: 117.52 (-0.41), ETSY: 10.26 (+0.06)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 455

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 501

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 431

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 427

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 305

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Daily Insights on WisdomTree Fund Prices and Holdings Update

Updated Category News Views 284

WisdomTree Fund Prices Overview In today’s ever-evolving financial landscape, understanding fund prices is crucial for investors. WisdomTree Issuer plc offers a range of funds that are pivotal to the investment strategy of many. With the latest updates from the fund market, let's delve into the details of some notable WisdomTree funds available for investment. Key...

Continue Reading
Impact of Drug Tariffs on American Patients and Insurers

Updated Category News Views 290

Understanding the Proposed Drug Tariffs Introduced by the Administration Recent discussions have centered around proposed 100% tariffs on foreign pharmaceuticals, primarily advocated by the administration. Economists warn that these tariffs will place a heavy financial burden on American patients and insurers rather than the foreign drug manufacturers. Economic Insights...

Continue Reading
AvidXchange Q2 2025 Results: Growth Amid Strategic Changes

Updated Category News Views 445

AvidXchange Reports Strong Financial Growth in Q2 2025 AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leader in accounts payable (AP) automation software, has published its financial results for the second quarter ended June 30, 2025. The company showcases growth despite various strategic changes, particularly surrounding its pending acquisition. Financial Highlights for Q2...

Continue Reading
Talkiatry Ranks #6 in Digital Health Innovation for 2024

Updated Category News Views 552

Talkiatry Achieves Recognition in Digital Health Talkiatry has been honored as the sixth most innovative digital health startup for 2024. This accolade is a testament to the significant impact the organization is making in the field of behavioral health care. Significance of the CB Insights Ranking Chosen by CB Insights, Talkiatry's ranking reflects a combination of...

Continue Reading
Innovative Partnership Enhances SBA Loan Accessibility for Businesses

Updated Category News Views 267

BizBuySell and LoanBud Collaboration Enhances Financing for Businesses BizBuySell, the leading business-for-sale marketplace, has teamed up with LoanBud, a fintech innovator specializing in SBA financing. This collaboration significantly transforms the experience of buying or selling small businesses by increasing transparency and clarity in the financing process from the...

Continue Reading